Abstract 1689TiP
Background
One of the unmet needs in Lung Cancer Care is the Stigma of patients due to the smoking habits; the condition of current smoker or former smoker causes the perception of the one’s incorrect lifestyle so, more than in other pathologies, patients with lung cancer are burdened with feelings of guilt and self-devaluation in anticipation of a negative social judgment. In addition to detecting this phenomenon, the study aims to psychologically support lung cancer patients, as well as smokers who belong to the Antismoking Centre in our Institute and who present with high levels of distress, through a psychotherapeutic path according to the EMDR (Eye Movement Desensitization and Reprocessing) model which could allow the reworking of traumatic or emotionally stressful moments, linked to the phases of the disease and to the personal history. The EMDR is one of the techniques that support smokers in quitting; the processing of the experience that occurs with EMDR allows the subject, through desensitization and cognitive restructuring, to change perspective and adopt more appropriate behaviors.
Trial design
Objectives of this study are the following: 1) to document the presence of stigma in current smokers or former smokers with lung cancer and subjects who undertake a smoke cessation program ; 2) to measure the correlation between stigma, level of anxiety, depression, quality of life and psychophysical well-being in the different phases of the disease starting from diagnosis and throughout treatment process;3) to investigate the impact and the efficacy of the EMDR model through the psychological re-evaluation of stress, depression and anxiety. The sociocultural, psychological factors and lifestyles of the participants will be investigated, including any gender-related differences regarding the Lung Cancer stigma, smoking habits and the outcome of a tobacco cessation process. A number of 45 subjects is planned to be recruited.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1636P - Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Presenter: Renée Bultijnck
Session: Poster session 11
1637P - Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
Presenter: Neeraj Agarwal
Session: Poster session 11
1638P - Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age
Presenter: Neal Shore
Session: Poster session 11
1639P - Self efficacy in people with prostate cancer in the UK: A large, digital survey
Presenter: Joe O'Sullivan
Session: Poster session 11
1640P - Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients
Presenter: Ziyun Wang
Session: Poster session 11
1641P - Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
Presenter: Christos Kyriakopoulos
Session: Poster session 11
1642P - Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis
Presenter: Charles Vauchier
Session: Poster session 11
1643P - Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Presenter: Bicky Thapa
Session: Poster session 11
1644P - PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Lana Broer
Session: Poster session 11
1645P - Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
Presenter: Marta Garcia De Herreros
Session: Poster session 11